Update shared on02 Sep 2025
Fair value Increased 7.75%BioArctic's consensus price target has been reduced to SEK280.50, primarily due to sharply lower revenue growth expectations and a significant drop in the projected future P/E multiple.
What's in the News
- BioArctic entered an option, collaboration, and license agreement with Novartis Pharma involving its proprietary BrainTransporter technology for a potential neurodegeneration treatment, receiving USD 30 million upfront, with up to USD 772 million in potential milestone payments and tiered royalties.
- The agreement allows Novartis to evaluate and potentially license drug candidates, while BioArctic retains BrainTransporter rights outside current partner agreements, highlighting future partnering opportunities.
- BioArctic announced positive interim safety results from the Phase 2a EXIST study of exidavnemab for Parkinson's disease and Multiple System Atrophy, enabling the start of additional higher-dose cohorts.
- Exidavnemab, a monoclonal antibody targeting pathological alpha-synuclein aggregates, has received orphan drug designation in the US and a positive opinion for orphan designation in the EU for Multiple System Atrophy.
Valuation Changes
Summary of Valuation Changes for BioArctic
- The Consensus Analyst Price Target has fallen slightly from SEK288.40 to SEK280.50.
- The Consensus Revenue Growth forecasts for BioArctic has significantly fallen from 12.8% per annum to 8.4% per annum.
- The Future P/E for BioArctic has significantly fallen from 66.77x to 53.52x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.